Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.

No abstract

INTRODUCTION: Fever, cough, leukocytosis and pulmonary infiltrates are typically associated with pneumonia. Rapid clinical deterioration despite adequate therapy should signal a search for other etiologies.